Royal Bank Of Canada Issues Positive Forecast for CorMedix (NASDAQ:CRMD) Stock Price

CorMedix (NASDAQ:CRMD) had its price objective boosted by Royal Bank Of Canada from $13.00 to $14.00 in a report released on Friday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Royal Bank Of Canada’s price target would suggest a potential upside of 81.11% from the company’s current price.

CRMD has been the subject of a number of other research reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of CorMedix in a report on Tuesday. Leerink Partners boosted their price objective on shares of CorMedix from $13.00 to $14.00 and gave the company an “outperform” rating in a report on Tuesday, April 28th. Citizens Jmp reaffirmed a “market outperform” rating and set a $19.00 price target on shares of CorMedix in a research report on Tuesday, April 28th. Needham & Company LLC boosted their price target on CorMedix from $14.00 to $15.00 and gave the company a “buy” rating in a research note on Monday, April 27th. Finally, D. Boral Capital reissued a “buy” rating and issued a $14.00 price objective on shares of CorMedix in a report on Monday, April 27th. Six investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $15.00.

CorMedix Trading Down 5.0%

CRMD traded down $0.41 on Friday, reaching $7.73. 857,616 shares of the company traded hands, compared to its average volume of 1,724,248. The firm has a fifty day simple moving average of $8.16 and a two-hundred day simple moving average of $7.65. The company has a quick ratio of 2.74, a current ratio of 2.97 and a debt-to-equity ratio of 0.33. CorMedix has a one year low of $6.13 and a one year high of $14.96. The company has a market cap of $606.42 million, a P/E ratio of 3.65 and a beta of 1.50.

CorMedix (NASDAQ:CRMD) last issued its quarterly earnings data on Thursday, August 13th. The company reported $0.29 EPS for the quarter, topping analysts’ consensus estimates of $0.28 by $0.01. CorMedix had a net margin of 45.25% and a return on equity of 45.57%. The company had revenue of $101.93 million during the quarter, compared to the consensus estimate of $96.04 million. As a group, equities research analysts expect that CorMedix will post 0.51 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. GSG Advisors LLC purchased a new stake in shares of CorMedix during the second quarter worth $126,000. Sanctuary Advisors LLC purchased a new position in CorMedix in the second quarter valued at $135,000. Quantbot Technologies LP acquired a new position in CorMedix during the 2nd quarter worth $85,000. Allworth Financial LP purchased a new stake in CorMedix during the 2nd quarter worth about $88,000. Finally, Planning Directions Inc. purchased a new stake in CorMedix during the 2nd quarter worth about $157,000. 34.18% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting CorMedix

Here are the key news stories impacting CorMedix this week:

• Positive Sentiment: CorMedix reported Q2 revenue of $101.9 million, above the roughly $96 million analyst consensus, while adjusted EBITDA reached $58.7 million and net income was $26.0 million. EPS of $0.29 also exceeded expectations. Growth was supported by continued DefenCath utilization and contributions from the Melinta portfolio. CRMD Stock Up as Q2 Earnings & Sales Beat on DefenCath, Melinta Gains
• Positive Sentiment: Management maintained its FY 2026 revenue outlook of $325 million to $345 million and raised adjusted EBITDA guidance, reinforcing expectations for strong profitability and operating leverage. CorMedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: The company expects to submit a supplemental filing for its fungal-disease treatment by the third quarter. Progress on this regulatory opportunity could provide an additional growth catalyst beyond DefenCath. CorMedix CEO expects supplemental filing for fungal disease treatment by Q3
• Neutral Sentiment: Brokerages currently assign CorMedix an average “Moderate Buy” recommendation, indicating generally favorable sentiment but not a uniformly bullish analyst view. CorMedix Given Average Recommendation of Moderate Buy
• Neutral Sentiment: Although the revenue outlook’s midpoint is broadly in line with consensus, investors may be taking profits or reassessing valuation after the initial earnings-driven rally. The stock remains below its 50-day moving average, adding to near-term volatility.

CorMedix Company Profile

CorMedix Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company’s lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers.

In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures.